A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
← catalyst calendarNCT06228326 · readout ≤ 193 d
Sponsored by Krystal Biotech, Inc. (industry) · KRYS — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
250estimated
Sites
14
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-17 | actual | When the study began enrolling |
| Primary completion | Feb 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2024-01-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Lung Cancer, Non-small Cell
- Lung Cancer Metastatic
- Solid Tumor, Adult
- Advanced Cancer
- Lung Cancer (NSCLC)
Interventions
- Biological: KB707
- Drug: Pembrolizumab (KEYTRUDA®)
- Drug: Chemotherapy
- Drug: Docetaxel
Primary outcome
what the primary-completion date above is the date OFTo evaluate the safety and tolerability of inhaled KB707 based upon assessment of adverse events (AE)
measured up to 36 months
Permalink · KRYS's whole pipeline · Catalyst calendar · Every registered study · What changed